STOCK TITAN

Ascendis Pharma A/S American Depositary Shares - ASND STOCK NEWS

Welcome to our dedicated page for Ascendis Pharma A/S American Depositary Shares news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma A/S American Depositary Shares stock.

Ascendis Pharma A/S (NASDAQ: ASND) is a pioneering biotechnology company located at 12 Tuborg Blvd., Hellerup, Capital Region of Denmark, Denmark. Specializing in the development of prodrug therapies, Ascendis Pharma is leveraging its proprietary TransCon technology to create therapies with improved efficacy and safety profiles that address significant unmet medical needs. The company’s diverse product pipeline includes TransCon growth hormone, TransCon peptides, TransCon PTH, and TransCon CNP, among others.

Ascendis Pharma operates across North America, China, and Europe, with the majority of its revenue derived from North American markets. The firm’s flagship product, SKYTROFA, has become the leading growth hormone product by value in the U.S. Ascendis is also rolling out YORVIPATH in Europe, starting with Germany and Austria. In addition, the company is advancing its clinical program for TransCon CNP.

In 2023, Ascendis undertook a significant restructuring to streamline its operations, processes, and expense allocations. President and CEO Jan Mikkelsen maintains that Ascendis is on track to achieve its ambitious Vision 3x3 and Vision 2030 goals, which include achieving blockbuster status for each of its three independent Endocrinology Rare Disease products and expanding its engine for future innovation.

Financially, Ascendis Pharma reported substantial revenue growth in 2023, with total revenue reaching €266.7 million compared to €51.2 million in 2022. This growth was primarily driven by higher SKYTROFA revenue and an upfront payment from Teijin. Research and development (R&D) expenses also increased to €413.5 million in 2023, reflecting ongoing development activities in their TransCon programs. Despite a net loss for the year, the company's financial health remains robust, with cash, cash equivalents, and marketable securities totaling €399.4 million as of December 31, 2023.

Looking ahead, Ascendis Pharma has several key milestones slated for 2024, including the expected commercial launch of TransCon PTH in the U.S. and advancing its oncology and ophthalmology programs. The company also plans to achieve operating cash flow breakeven on a quarterly basis by the end of the year.

Ascendis continues to focus on leveraging its TransCon technology to develop therapies that can make a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis Pharma is committed to becoming a leading, fully integrated biopharma company.

Rhea-AI Summary

Ascendis Pharma reported significant financial results for 2022, with total revenue of €51.2 million, up from €7.8 million in 2021. The increase is largely attributed to SKYTROFA U.S. sales reaching €35.7 million. However, the company incurred a net loss of €583.2 million, compared to €383.6 million in 2021. Key milestones include the PDUFA date for TransCon PTH set for April 30, 2023, and an anticipated launch of SKYTROFA in Germany in Q3 2023. The company ended 2022 with €742.9 million in cash and equivalents, down from €789.6 million in 2021, highlighting the need for ongoing funding amidst rising R&D and SG&A expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) will host a conference call and webcast on February 16, 2023, at 4:30 p.m. ET to discuss its 2022 financial results and provide a business update. The event can be accessed through their website or by registering for the teleconference. Ascendis utilizes its innovative TransCon platform to develop therapies aimed at improving patient outcomes, positioning itself as a leading global biopharmaceutical company. However, the company warns of risks related to third-party dependencies, unforeseen expenses, and external market factors impacting its operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary

The report titled "Non-Viral / Intracellular Drug Delivery Systems Market" by ResearchAndMarkets.com highlights the rising demand for efficient drug delivery systems in the biopharmaceutical industry. It notes that over 20% of the proteome resides within cell membranes, necessitating innovative delivery methods for therapeutic intervention. Key advancements include non-viral systems such as exosome-based techniques and cell-penetrating peptides. The report reveals that around 1,300 patents have been filed, indicating substantial innovation, with over 20,000 studies on oligonucleotide-based therapeutics underway. The market is expected to grow significantly in the near term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
Rhea-AI Summary

Ascendis Pharma (ASND) reported a positive update on its Vision 3x3 strategic plan, spotlighting upcoming milestones for 2023. Key developments include the anticipated launch of TransCon PTH for hypoparathyroidism, with FDA Priority Review due on April 30, 2023. The company also expects topline results from the Phase 3 foresiGHt Trial in Q4 2023 and plans to launch SKYTROFA in Germany by Q3 2023. TransCon CNP's Phase 2 trials show potential for children with achondroplasia, marking advances across its endocrinology, oncology, and ophthalmology pipelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.81%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma announces the opening of the online portal for the Expanded Access Program (EAP) allowing physicians to request access to TransCon PTH for eligible patients in the U.S. This investigational parathyroid hormone replacement therapy is currently under Priority Review by the FDA, with a PDUFA date set for April 30, 2023. Patients eligible for the program must be adults diagnosed with hypoparathyroidism and meet specific inclusion and exclusion criteria. The move aims to address the needs of the hypopara community while awaiting potential FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The event takes place in San Francisco, CA, from 12:00 to 12:40 p.m. Eastern Time. A live webcast will be available on the Ascendis Pharma website, with a replay accessible for 30 days post-event. The company focuses on integrating a global biopharma approach using its TransCon platform aimed at developing innovative therapies to improve patient lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
Rhea-AI Summary

Ascendis Pharma (ASND) announced an expanded access program for its investigational therapy, TransCon PTH, aimed at patients with hypoparathyroidism in the U.S. The program allows eligible patients, who cannot access other treatments, to request this therapy through their physicians. TransCon PTH is currently under FDA Priority Review, with a target PDUFA date of April 30, 2023. The company emphasizes its commitment to addressing the urgent needs of the hypopara community while underscoring that TransCon PTH's safety and efficacy are not yet established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma (Nasdaq: ASND) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. The event, hosted virtually, features a fireside chat with the company's executives, scheduled from 1:00 PM to 1:20 PM Eastern Time.

A live webcast will be accessible via the Ascendis Pharma website, with a replay available for 30 days post-event. Ascendis Pharma focuses on innovative therapies using its TransCon technology to enhance patient care, with operations in multiple global locations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
Rhea-AI Summary

Ascendis Pharma has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for TransCon PTH, a potential first treatment for hypoparathyroidism. This condition affects an estimated 85,000-223,000 patients in Europe and currently lacks effective hormonal replacement therapy. The MAA is based on data from the Phase 3 PaTHway Trial, where 77 out of 79 patients continued treatment, indicating strong efficacy and tolerability. The FDA is currently reviewing TransCon PTH, with a target action date of April 30, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.45%
Tags
none
Rhea-AI Summary

Ascendis Pharma announced positive topline results from the ACcomplisH Trial, a Phase 2 study evaluating the efficacy of once-weekly TransCon CNP in children with achondroplasia. The trial demonstrated a statistically significant improvement in annualized height velocity (AHV) at 52 weeks for the 100 µg/kg/week dose compared to placebo (p=0.0218). Remarkably, all 57 participants completed the trial, indicating robust tolerability. These findings support further development of TransCon CNP as a treatment option for achondroplasia. Ascendis will discuss these results in a conference call on November 14, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.45%
Tags

FAQ

What is the current stock price of Ascendis Pharma A/S American Depositary Shares (ASND)?

The current stock price of Ascendis Pharma A/S American Depositary Shares (ASND) is $138.79 as of December 24, 2024.

What is the market cap of Ascendis Pharma A/S American Depositary Shares (ASND)?

The market cap of Ascendis Pharma A/S American Depositary Shares (ASND) is approximately 8.3B.

What is Ascendis Pharma A/S's primary focus?

Ascendis Pharma A/S focuses on developing prodrug therapies using its proprietary TransCon technology to meet significant unmet medical needs.

Where is Ascendis Pharma A/S located?

Ascendis Pharma A/S is located at 12 Tuborg Blvd., Hellerup, Capital Region of Denmark, Denmark.

What are some of Ascendis Pharma's key products?

Key products include SKYTROFA, YORVIPATH, TransCon growth hormone, TransCon peptides, TransCon PTH, and TransCon CNP.

In which regions does Ascendis Pharma operate?

Ascendis Pharma operates in North America, China, and Europe.

What were Ascendis Pharma's total revenues for 2023?

In 2023, Ascendis Pharma reported total revenues of €266.7 million.

What major milestones does Ascendis Pharma plan to achieve in 2024?

In 2024, Ascendis Pharma plans to launch TransCon PTH in the U.S. and continue advancing its oncology and ophthalmology programs.

What is the Vision 2030 goal for Ascendis Pharma?

The Vision 2030 goal includes achieving blockbuster status for each of its three independent Endocrinology Rare Disease products and expanding its engine for future innovation.

How much cash and marketable securities did Ascendis Pharma have at the end of 2023?

As of December 31, 2023, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €399.4 million.

What technology platform does Ascendis Pharma use for developing its therapies?

Ascendis Pharma uses its innovative TransCon technology platform to develop its therapies.

What are Ascendis Pharma's core values?

Ascendis Pharma's core values are Patients, Science, and Passion.

Ascendis Pharma A/S American Depositary Shares

Nasdaq:ASND

ASND Rankings

ASND Stock Data

8.30B
60.07M
0.73%
107.12%
5.7%
Biotechnology
Healthcare
Link
United States of America
Hellerup